Literature DB >> 16619288

Intranasal immunisation with inactivated RSV and bacterial adjuvants induces mucosal protection and abrogates eosinophilia upon challenge.

Nathalie Etchart1, Bas Baaten, Svein Rune Andersen, Lisa Hyland, Simon Y C Wong, Sam Hou.   

Abstract

We have previously shown that following intranasal exposure to influenza virus, specific plasma cells are generated in the nasal-associated lymphoid tissue (NALT) and maintained for the life of the animal. However, we also showed that following infection with respiratory syncytial virus (RSV), specific plasma cells are generated in the NALT but wane quickly and are not maintained even after challenge, even though RSV-specific serum antibody responses remain robust. Only infection with influenza virus generated sterilising immunity, implying a role for these long-lived plasma cells in protection. We show here that the RSV-specific IgA NALT plasma cell population and lung antibody levels can be substantially boosted, both at acute and memory time points, by intranasal immunisation with inactivated RSV (iRSV) in combination with bacterial outer membrane vesicles (OMV) compared to live RSV alone. Finally, challenge with live RSV showed that immunisation with iRSV and OMV protect against both virus replication in the lung and the eosinophil infiltrate generated by either live RSV or iRSV alone. These data show that immunisation with iRSV and OMV maintains a NALT RSV-specific plasma cell population and generates an efficient protective immune response following RSV infection.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16619288     DOI: 10.1002/eji.200535493

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  12 in total

Review 1.  Outer membrane vesicles for vaccination and targeted drug delivery.

Authors:  Sihan Wang; Jin Gao; Zhenjia Wang
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2018-04-26

Review 2.  Immune modulation by bacterial outer membrane vesicles.

Authors:  Maria Kaparakis-Liaskos; Richard L Ferrero
Journal:  Nat Rev Immunol       Date:  2015-05-15       Impact factor: 53.106

3.  Nasal immunity to staphylococcal toxic shock is controlled by the nasopharynx-associated lymphoid tissue.

Authors:  Stefan Fernandez; Emily D Cisney; Shannan I Hall; Robert G Ulrich
Journal:  Clin Vaccine Immunol       Date:  2011-02-16

4.  CXCR6 is a marker for protective antigen-specific cells in the lungs after intranasal immunization against Mycobacterium tuberculosis.

Authors:  Lian Ni Lee; Edward O Ronan; Catherine de Lara; Kees L M C Franken; Tom H M Ottenhoff; Elma Z Tchilian; Peter C L Beverley
Journal:  Infect Immun       Date:  2011-05-31       Impact factor: 3.441

5.  Protective T cell immunity against respiratory syncytial virus is efficiently induced by recombinant BCG.

Authors:  Susan M Bueno; Pablo A González; Kelly M Cautivo; Jorge E Mora; Eduardo D Leiva; Hugo E Tobar; Glenn J Fennelly; Eliseo A Eugenin; William R Jacobs; Claudia A Riedel; Alexis M Kalergis
Journal:  Proc Natl Acad Sci U S A       Date:  2008-12-15       Impact factor: 11.205

6.  Fusobacterium nucleatum envelope protein FomA is immunogenic and binds to the salivary statherin-derived peptide.

Authors:  Hidetaka Nakagaki; Shinichi Sekine; Yutaka Terao; Masahiro Toe; Muneo Tanaka; Hiro-O Ito; Shigetada Kawabata; Satoshi Shizukuishi; Kohtaro Fujihashi; Kosuke Kataoka
Journal:  Infect Immun       Date:  2009-12-14       Impact factor: 3.441

Review 7.  Mouse models for the study of mucosal vaccination against otitis media.

Authors:  Albert Sabirov; Dennis W Metzger
Journal:  Vaccine       Date:  2008-02-04       Impact factor: 3.641

8.  Intranasal immunization of mice with a bovine respiratory syncytial virus vaccine induces superior immunity and protection compared to those by subcutaneous delivery or combinations of intranasal and subcutaneous prime-boost strategies.

Authors:  John W Mapletoft; Laura Latimer; Lorne A Babiuk; Sylvia van Drunen Littel-van den Hurk
Journal:  Clin Vaccine Immunol       Date:  2009-10-28

9.  Single intranasal immunization with recombinant adenovirus-based vaccine induces protective immunity against respiratory syncytial virus infection.

Authors:  Jae-Rang Yu; Sol Kim; Jee-Boong Lee; Jun Chang
Journal:  J Virol       Date:  2007-12-19       Impact factor: 5.103

10.  Multifunctional, high-level cytokine-producing Th1 cells in the lung, but not spleen, correlate with protection against Mycobacterium tuberculosis aerosol challenge in mice.

Authors:  Emily K Forbes; Clare Sander; Edward O Ronan; Helen McShane; Adrian V S Hill; Peter C L Beverley; Elma Z Tchilian
Journal:  J Immunol       Date:  2008-10-01       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.